Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

71.4%

5 terminated/withdrawn out of 7 trials

Success Rate

28.6%

-57.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 1(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02468414Phase 2Terminated

TARGTEPO Treatment for Anemia in PD US Trial

Role: collaborator

NCT02117427Phase 1Completed

TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

Role: collaborator

NCT02378662Phase 2Terminated

TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

Role: collaborator

NCT01433133Phase 1Terminated

Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients

Role: lead

NCT01555515Phase 1Terminated

Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant

Role: lead

NCT00542568Phase 1Completed

Safety and Efficacy of Sustained Erythropoietin Therapy

Role: lead

NCT01430000Phase 1Withdrawn

Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump

Role: lead

All 7 trials loaded